Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
NCT02941549
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
OTHER:
Placebo capsules
DRUG:
Epeleuton
Sponsor
Afimmune